About this data
What it is
When a company's officers, directors or owners of more than 10% buy or sell its stock, they must report the trade to the SEC on Form 4. This feed shows purchases and sales on the open market; stock grants, option exercises and shares withheld for tax are left out.
Who files it
The insider, usually through the company, within two business days of the trade.
How current
We collect new filings throughout the day on SEC business days.
Worth knowing
Sales are often routine: insiders sell to diversify, to pay taxes, or under a 10b5-1 plan set up months in advance. A purchase with their own money is less common, which is why many investors pay closer attention to it.

All of this comes from public filings.

Open-market trades per day, last 30 days

05001,000Oct 17 · Purchases: 0Oct 17 · Sales: 0Oct 17Oct 18 · Purchases: 0Oct 18 · Sales: 0Oct 19 · Purchases: 29Oct 19 · Sales: 159Oct 20 · Purchases: 45Oct 20 · Sales: 209Oct 21 · Purchases: 38Oct 21 · Sales: 183Oct 21Oct 22 · Purchases: 50Oct 22 · Sales: 130Oct 23 · Purchases: 77Oct 23 · Sales: 126Oct 24 · Purchases: 1Oct 24 · Sales: 0Oct 25 · Purchases: 0Oct 25 · Sales: 0Oct 25Oct 26 · Purchases: 60Oct 26 · Sales: 171Oct 27 · Purchases: 27Oct 27 · Sales: 217Oct 28 · Purchases: 44Oct 28 · Sales: 135Oct 29 · Purchases: 35Oct 29 · Sales: 199Oct 29Oct 30 · Purchases: 68Oct 30 · Sales: 270Oct 31 · Purchases: 3Oct 31 · Sales: 0Nov 1 · Purchases: 2Nov 1 · Sales: 0Nov 2 · Purchases: 79Nov 2 · Sales: 826Nov 2Nov 3 · Purchases: 66Nov 3 · Sales: 337Nov 4 · Purchases: 67Nov 4 · Sales: 535Nov 5 · Purchases: 108Nov 5 · Sales: 458Nov 6 · Purchases: 137Nov 6 · Sales: 390Nov 6Nov 7 · Purchases: 0Nov 7 · Sales: 0Nov 8 · Purchases: 0Nov 8 · Sales: 0Nov 9 · Purchases: 110Nov 9 · Sales: 457Nov 10 · Purchases: 97Nov 10 · Sales: 406Nov 10Nov 11 · Purchases: 98Nov 11 · Sales: 330Nov 12 · Purchases: 54Nov 12 · Sales: 167Nov 13 · Purchases: 23Nov 13 · Sales: 28Nov 14 · Purchases: 0Nov 14 · Sales: 0Nov 14Nov 15 · Purchases: 0Nov 15 · Sales: 0
05001,000Oct 17 · Purchases: 0Oct 17 · Sales: 0Oct 17Oct 18 · Purchases: 0Oct 18 · Sales: 0Oct 19 · Purchases: 29Oct 19 · Sales: 159Oct 20 · Purchases: 45Oct 20 · Sales: 209Oct 21 · Purchases: 38Oct 21 · Sales: 183Oct 21Oct 22 · Purchases: 50Oct 22 · Sales: 130Oct 23 · Purchases: 77Oct 23 · Sales: 126Oct 24 · Purchases: 1Oct 24 · Sales: 0Oct 25 · Purchases: 0Oct 25 · Sales: 0Oct 25Oct 26 · Purchases: 60Oct 26 · Sales: 171Oct 27 · Purchases: 27Oct 27 · Sales: 217Oct 28 · Purchases: 44Oct 28 · Sales: 135Oct 29 · Purchases: 35Oct 29 · Sales: 199Oct 29Oct 30 · Purchases: 68Oct 30 · Sales: 270Oct 31 · Purchases: 3Oct 31 · Sales: 0Nov 1 · Purchases: 2Nov 1 · Sales: 0Nov 2 · Purchases: 79Nov 2 · Sales: 826Nov 2Nov 3 · Purchases: 66Nov 3 · Sales: 337Nov 4 · Purchases: 67Nov 4 · Sales: 535Nov 5 · Purchases: 108Nov 5 · Sales: 458Nov 6 · Purchases: 137Nov 6 · Sales: 390Nov 6Nov 7 · Purchases: 0Nov 7 · Sales: 0Nov 8 · Purchases: 0Nov 8 · Sales: 0Nov 9 · Purchases: 110Nov 9 · Sales: 457Nov 10 · Purchases: 97Nov 10 · Sales: 406Nov 10Nov 11 · Purchases: 98Nov 11 · Sales: 330Nov 12 · Purchases: 54Nov 12 · Sales: 167Nov 13 · Purchases: 23Nov 13 · Sales: 28Nov 14 · Purchases: 0Nov 14 · Sales: 0Nov 14Nov 15 · Purchases: 0Nov 15 · Sales: 0

Purchases Sales

By trade date. Insiders have two business days to file, so the most recent days fill in later.

Latest open-market insider trades

Reset

Showing: ticker PTGX

Latest open-market insider trades
TradedInsiderCompanyTypeSharesPriceValueFiling
Sep 10, 2026Patel Dinesh V PH D
President and CEO, Director
PTGX
Protagonist Therapeutics, Inc.
Sale7,278$144.10$1.0M SaleForm 4 ↗
Sep 9, 2026Patel Dinesh V PH D
President and CEO, Director
PTGX
Protagonist Therapeutics, Inc.
Sale63,548$146.18$9.3M SaleForm 4 ↗
Sep 8, 2026Patel Dinesh V PH D
President and CEO, Director
PTGX
Protagonist Therapeutics, Inc.
Sale54,174$145.87$7.9M SaleForm 4 ↗
Aug 11, 2026Patel Dinesh V PH D
President and CEO, Director
PTGX
Protagonist Therapeutics, Inc.
Sale34,239$148.52$5.1M SaleForm 4 ↗
Aug 10, 2026Patel Dinesh V PH D
President and CEO, Director
PTGX
Protagonist Therapeutics, Inc.
Sale65,761$149.11$9.8M SaleForm 4 ↗
Jun 23, 2026William D. Waddill
Director
PTGX
Protagonist Therapeutics, Inc.
Sale9,000$117.94$1.1M SaleForm 4 ↗
Jun 10, 2026William D. Waddill
Director
PTGX
Protagonist Therapeutics, Inc.
Sale9,000$107.68$969.1K SaleForm 4 ↗
May 29, 2026William D. Waddill
Director
PTGX
Protagonist Therapeutics, Inc.
Sale9,000$99.64$896.8K SaleForm 4 ↗
May 12, 2026Patel Dinesh V PH D
President and CEO, Director
PTGX
Protagonist Therapeutics, Inc.
Sale75,000$100.12$7.5M SaleForm 4/A ↗
May 8, 2026Bryan Giraudo
Director
PTGX
Protagonist Therapeutics, Inc.
Sale5,130$100.00$513.0K SaleForm 4 ↗
May 8, 2026Bryan Giraudo
Director
PTGX
Protagonist Therapeutics, Inc.
Sale6,000$100.00$600.0K SaleForm 4 ↗
May 7, 2026Bryan Giraudo
Director
PTGX
Protagonist Therapeutics, Inc.
Sale12,000$100.07$1.2M SaleForm 4 ↗
May 7, 2026Bryan Giraudo
Director
PTGX
Protagonist Therapeutics, Inc.
Sale36,000$100.14$3.6M SaleForm 4 ↗
Apr 20, 2026Ali Asif
Chief Financial Officer
PTGX
Protagonist Therapeutics, Inc.
Sale1,750$105.47$184.6K SaleForm 4 ↗
Mar 26, 2026Arturo Molina MD
Chief Medical Officer
PTGX
Protagonist Therapeutics, Inc.
Sale15,000$104.79$1.6M SaleForm 4 ↗
Mar 26, 2026Harold E. Selick
Director
PTGX
Protagonist Therapeutics, Inc.
Sale24,000$105.00$2.5M SaleForm 4 ↗
Mar 26, 2026Ali Asif
Chief Financial Officer
PTGX
Protagonist Therapeutics, Inc.
Sale24,765$104.24$2.6M SaleForm 4 ↗
Mar 25, 2026Patel Dinesh V PH D
President and CEO, Director
PTGX
Protagonist Therapeutics, Inc.
Sale54,641$101.00$5.5M SaleForm 4 ↗
Mar 24, 2026Patel Dinesh V PH D
President and CEO, Director
PTGX
Protagonist Therapeutics, Inc.
Sale59$101.00$5,959 SaleForm 4 ↗
Feb 17, 2026Lewis T. Williams
Director
PTGX
Protagonist Therapeutics, Inc.
Sale18,000$82.42$1.5M SaleForm 4 ↗
Feb 6, 2026William D. Waddill
Director
PTGX
Protagonist Therapeutics, Inc.
Sale20,000$83.68$1.7M SaleForm 4 ↗
Jan 27, 2026Patel Dinesh V PH D
President and CEO, Director
PTGX
Protagonist Therapeutics, Inc.
Sale4,068$83.19$338.4K SaleForm 4 ↗
Jan 27, 2026Ali Asif
Chief Financial Officer
PTGX
Protagonist Therapeutics, Inc.
Sale18,203$83.14$1.5M SaleForm 4 ↗
Jan 27, 2026Ali Asif
Chief Financial Officer
PTGX
Protagonist Therapeutics, Inc.
Sale28,000$83.13$2.3M SaleForm 4 ↗
Jan 27, 2026Arturo Molina MD
Chief Medical Officer
PTGX
Protagonist Therapeutics, Inc.
Sale5,000$82.00$410.0K SaleForm 4 ↗
Jan 26, 2026Patel Dinesh V PH D
President and CEO, Director
PTGX
Protagonist Therapeutics, Inc.
Sale14,205$84.05$1.2M SaleForm 4 ↗
Jan 26, 2026Patel Dinesh V PH D
President and CEO, Director
PTGX
Protagonist Therapeutics, Inc.
Sale10,685$84.00$897.5K SaleForm 4 ↗
Jan 26, 2026Arturo Molina MD
Chief Medical Officer
PTGX
Protagonist Therapeutics, Inc.
Sale5,000$82.28$411.4K SaleForm 4 ↗
Jan 23, 2026Patel Dinesh V PH D
President and CEO, Director
PTGX
Protagonist Therapeutics, Inc.
Sale19,315$84.59$1.6M SaleForm 4 ↗
Jan 23, 2026Arturo Molina MD
Chief Medical Officer
PTGX
Protagonist Therapeutics, Inc.
Sale13,151$82.42$1.1M SaleForm 4 ↗
Jan 20, 2026Arturo Molina MD
Chief Medical Officer
PTGX
Protagonist Therapeutics, Inc.
Sale9,514$82.48$784.7K SaleForm 4 ↗
Jan 20, 2026Patel Dinesh V PH D
President and CEO, Director
PTGX
Protagonist Therapeutics, Inc.
Sale34,438$82.48$2.8M SaleForm 4 ↗
Jan 20, 2026Ali Asif
Chief Financial Officer
PTGX
Protagonist Therapeutics, Inc.
Sale8,588$82.48$708.3K SaleForm 4 ↗
Nov 17, 2025Arturo Molina MD
Chief Medical Officer
PTGX
Protagonist Therapeutics, Inc.
Sale2,712$84.77$229.9K SaleForm 4 ↗
Oct 10, 2025William D. Waddill
Director
PTGX
Protagonist Therapeutics, Inc.
Sale8,000$87.81$702.5K SaleForm 4 ↗
Oct 10, 2025William D. Waddill
Director
PTGX
Protagonist Therapeutics, Inc.
Sale4,000$69.25$277.0K SaleForm 4 ↗
Sep 22, 2025William D. Waddill
Director
PTGX
Protagonist Therapeutics, Inc.
Sale4,000$64.25$257.0K SaleForm 4 ↗
Aug 27, 2025William D. Waddill
Director
PTGX
Protagonist Therapeutics, Inc.
Sale4,000$59.25$237.0K SaleForm 4 ↗
Jul 25, 2025Patel Dinesh V PH D
President and CEO, Director
PTGX
Protagonist Therapeutics, Inc.
Sale10,415$54.78$570.5K SaleForm 4 ↗
Jul 23, 2025Patel Dinesh V PH D
President and CEO, Director
PTGX
Protagonist Therapeutics, Inc.
Sale17,520$54.79$959.9K SaleForm 4 ↗
Jul 22, 2025Patel Dinesh V PH D
President and CEO, Director
PTGX
Protagonist Therapeutics, Inc.
Sale22,065$55.05$1.2M SaleForm 4 ↗
Jul 21, 2025Patel Dinesh V PH D
President and CEO, Director
PTGX
Protagonist Therapeutics, Inc.
Sale12,859$54.86$705.4K SaleForm 4 ↗
Jun 10, 2025Arturo Molina MD
Chief Medical Officer
PTGX
Protagonist Therapeutics, Inc.
Sale10,000$57.03$570.3K SaleForm 4 ↗
Jun 9, 2025Arturo Molina MD
Chief Medical Officer
PTGX
Protagonist Therapeutics, Inc.
Sale10,000$55.51$555.1K SaleForm 4 ↗
Apr 22, 2025Ali Asif
Chief Financial Officer
PTGX
Protagonist Therapeutics, Inc.
Sale1,756$46.00$80.8K SaleForm 4 ↗
Mar 17, 2025William D. Waddill
Director
PTGX
Protagonist Therapeutics, Inc.
Sale4,000$54.25$217.0K SaleForm 4 ↗
Mar 13, 2025Arturo Molina MD
Chief Medical Officer
PTGX
Protagonist Therapeutics, Inc.
Sale30,514$55.74$1.7M SaleForm 4 ↗
Mar 12, 2025Ali Asif
Chief Financial Officer
PTGX
Protagonist Therapeutics, Inc.
Sale24,903$58.73$1.5M SaleForm 4 ↗
Feb 19, 2025Patel Dinesh V PH D
President and CEO, Director
PTGX
Protagonist Therapeutics, Inc.
Sale5,359$38.18$204.6K SaleForm 4 ↗
Jan 16, 2025Arturo Molina MD
Chief Medical Officer
PTGX
Protagonist Therapeutics, Inc.
Sale3,252—$0 SaleForm 4 ↗

The newest 50 items, most recent first. Every row links to its original filing. Updated Nov 15, 2026, 6:44 PM EST.

Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.

Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances